MÆDICA - a Journal of Clinical Medicine Logo
  • Home
  • Profile
  • Standards
    • Types of articles
    • Instructions for authors
    • Editing rules (peer-review protocol)
    • Official Journal’s protocols
  • Editorial Council
  • Peer-review TEAM
  • How to
  • Menu

Author archives

  • About
  • Latest Posts

Anca CIOBANU

Latest posts by Anca CIOBANU (see all)

  • Pregnancy Management in Women with Antiphospholidic Syndrome - July 19, 2019
  • Indolent Lymphoma: Diagnosis and Prognosis in Medical Practice - July 2, 2015
  • The Impact of 2-(18) Fluoro-2- Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Treatment Strategy of Hodgkin Lymphoma-Current Hematologic Concepts - June 30, 2015

Articles signed on MÆDICA, JCM:

Pregnancy Management in Women with Antiphospholidic Syndrome

SELECT ISSUE


MÆDICA - a Journal of Clinical Medicine | Vol. 14, No. 2, 2019
CNCSIS - CMR - B+ OBBCSSR

Members Area


Pregnancy Management in Women with Antiphospholidic Syndrome

Andreea RADU, Stefan Cristian DUDU, Anca CIOBANU, Gheorghe PELTECU, George IANCU, Radu BOTEZATU, Nicolae GICA and Anca-Maria PANAITESCU

ABSTRACT

The antiphospholipid syndrome (APS or Hughes Syndrome) is a systemic autoimmune disease characterised by the presence of specific and persistent circulating antiphospholipid antibodies (APL) and the subsequent morbidities they cause, including pregnancy complications and thrombosis.
The three main antiphospholipid antibodies are: lupus anticoagulant (LA); anticardiolipin antibodies (aCL) IgG and IgM; and anti-β2-glycoprotein 1 IgG and IgM antibodies.
Antiphospholipid syndrome is associated with pregnancy complications such as recurrent early fetal loss, fetal death, preeclampsia (PE), and fetal growth restriction (FGR).
Although autoimmune disorders may have serious implication during pregnancy important advancements in pregnancy outcome have been reported in women with APL. The challenge arises in case of women refractory to conventional treatment (heparine/aspirin combination), which occurs in about 20-30% of cases. The management of pregnant women with non-criteria APS manifestations and that of APL carriers during their first pregnancy is also discussed.
This paper aims to discuss the risk stratification, clinical and pregnancy implications and current treatment strategies for pregnant women.
Keywords: autoimmune disease, antiphospholipid syndrome, antiphospholipid antibodies, recurrent miscarriages, thrombosis

Full text | PDF

Indolent Lymphoma: Diagnosis and Prognosis in Medical Practice

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 8, nr. 4, 2013

CNCSIS - CMR - B+ OBBCSSR

HIGHLIGHTS

What is plagiarism

Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


Indolent Lymphoma: Diagnosis and Prognosis in Medical Practice

Anca CIOBANU, Oana STANCA, Irina TRIANTAFYLLIDIS and Anca LUPU

ABSTRACT

Introduction: Non-Hodgkin lymphomas represent malignant tumors of lymphoid cells. These chronic lymphoproliferative disorders stand for malignancies with varied histological aspects, clinical features, evolution, prognosis and aggressiveness. Follicular lymphomas are the most frequent form of indolent lymphomas and they represent around 25% of all malignant lymphomas in adults.

Material and method: Between 2011 and 2012, we have retrospectively observed, analyzed and described a group of 24 patients diagnosed with follicular lymphomas in the Department of Hematology from Coltea Hospital. The admittance criteria were: age, gender, hemoglobin and LDH levels, number lymph nodes affected and the Ann Arbor lymphoma staging system. Also used as patient study parameters were the following immunohistochemical criteria: CD20, UCHL1, CD79a, expression of Bcl 2 and Bcl 6, CD10 and the proliferative index (Ki-67).

Results: Multiple studies have shown that prognosis depends far more on clinical and histology parameters, including age, the presence of extra-node diseases and the performance status. In our study, regarding the ratio between the two genders, the male patients were more numerous than the female patients. The impairment of the male patients is associated with an unfavorable prognosis. From the age perspective, most of the diagnosed patients were part of the age group over 60. The age exceeding 60 is considered a negative prognosis factor. The serum lactate dehydrogenase (LDH) level is also considered an unfavorable prognosis factor. In our study, stage III and IV were frequently and this represents a poor prognosis factor.

Conclusions: Although it was a small number of patients, the results obtained correspond to the results existing in literature

Keywords: Follicular lymphoma, diagnosis, prognosis

Full text | PDF

The Impact of 2-(18) Fluoro-2- Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Treatment Strategy of Hodgkin Lymphoma-Current Hematologic Concepts

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 10, nr. 2, 2015

CNCSIS - CMR - B+ OBBCSSR

HIGHLIGHTS

What is plagiarism

Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


The Impact of 2-(18) Fluoro-2- Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Treatment Strategy of Hodgkin Lymphoma-Current Hematologic Concepts

Oana STANCA, Anca Roxana LUPU, Anca CIOBANU, Irina TRIANTAFYLLIDIS, Cecilia GHIMICI and Ileana Delia MUT

ABSTRACT

Positron emission tomography/computed tomography (PET/CT) is useful in staging of Hodgkin lymphoma (HL), for early response – adapted therapy and choosing an individualized therapy, and is useful in determination of disease extent in relapsed and refractory Hodgkin lymphoma. Interim PET using 2-(18) fluoro-2-deoxyglucose(FDG) and low dose CT performed in one scanning session (FDG-PET/ CT) helps to predict outcome in Hodgkin lymphoma and to asses therapeutic stratification.

Keywords: PET/CT, Hodgkin lymphoma, stage, response to treatment

Full text | PDF



plic-mail[email protected]

 Terms and conditions

© MÆDICA - a Journal of Clinical Medicine - All rights reserved